Safety and Efficacy of MP-214 in Patients With Schizophrenia
NCT ID: NCT01625000
Last Updated: 2026-01-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
512 participants
INTERVENTIONAL
2012-05-31
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-Term Study of MP-214 in Patients With Schizophrenia
NCT01626872
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
NCT01625897
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia
NCT02418819
A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study
NCT00567710
A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.
NCT00250367
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MP-214 3mg
MP-214 3mg
Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.
MP-214 6mg
MP-214 6mg
Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.
MP-214 9mg
MP-214 9mg
Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.
Risperidone 4mg
Risperidone 4mg
Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.
Placebo
Placebo
Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MP-214 3mg
Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.
MP-214 6mg
Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.
MP-214 9mg
Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.
Risperidone 4mg
Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.
Placebo
Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients diagnosed with schizophrenia according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia
* Patients with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG)
Exclusion Criteria
The information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
20 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanabe Pharma Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sapporo, Hokkaido, Japan
Seoul, , South Korea
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A002-A4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.